Mannkind expects Q4 revenue of about $38 million, plus or minus. Natetanib DPI moves toward Phase 2 in the U.S. after FDA feedback.
MNKD · Mannkind Corp · Documents
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →
Mankind Corporation reported third-quarter revenue of $101.9 million, up 24%, while roughly 75% of Furosix shipments had moved to ReadyFlow by late October. It expects record fourth-quarter revenue to drive profitability.
For the nine months ended September 30, 2026, Mannkind reported 27% total revenue growth, a $58.9 million net loss and a $36.9 million, or 73%, increase in commercial product gross profit.
MannKind reported Q3 2026 total revenues of $101.9 million, up 24% from Q3 2025, as commercial product revenue reached $45.0 million. Furoscix ReadyFlow shipments began in mid-September and represented approximately 75% of current weekly Furoscix shipments.
Mannkind said inhaled natetanib is entering phase 2 with about 140 patients testing two doses in about 12 or 13 countries, after initial dosing showed no diarrhea or cough-related discontinuations.